Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 92,832

Document Document Title
WO/2024/048899A1
The present invention relates to a pharmaceutical composition for alleviating or treating sequelae of cerebral infarction, comprising glia-like cells differentiated from a human mesenchymal stem cell (hMSC). The pharmaceutical compositio...  
WO/2024/048479A1
The present invention relates to the inhibition of ischemia-reperfusion injury by the use of glutathione persulfide as well as the use of the same in lung transplantation and pulmonary edema treatment. Specifically, the present invention...  
WO/2024/050539A1
Provided herein are crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-di oxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde, compositions thereof, methods of preparation thereof, and methods of their uses.  
WO/2024/045250A1
A DNA tetrahedral pharmaceutical complex for treating neovascular retinal diseases, which is a complex formed by TDNs carrying Bevasiranib. The complex exhibits an excellent inhibitory effect on neovascularization, significantly improves...  
WO/2024/047130A1
Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and ...  
WO/2024/047094A1
A pharmaceutical formulation which comprises Compound 1, one or more pharmaceutical fillers, one or more pharmaceutical disintegrants, and one or more pharmaceutical lubricant.  
WO/2024/048528A1
The present invention provides a mechanosignaling inhibitor containing a substance capable of suppressing the expression or function of LSMEM2 as an active ingredient.  
WO/2024/048519A1
Provided are: a pyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; a pharmaceutical use thereof, etc. A compou...  
WO/2024/050526A1
The present disclosure provides anti-KCNQl humanized antibodies and their use in treating long QT syndrome (LQTS).  
WO/2024/048683A1
The present invention provides a novel substance that suitably functions as an Met agonist. The present invention provides an artificial protein that includes an antibody Fc region, where an amino acid represented by SEQ ID NO: 1 is inse...  
WO/2024/047208A1
The present invention relates to an oral fixed-dose immediate release pharmaceutical composition of 2.5 mg of rivaroxaban and 50 mg of acetylsalicylic acid for use in a prevention of atherothrombotic events in adult patients after an acu...  
WO/2024/046297A1
Provided are a siRNA for inhibiting the expression of an asialoglycoprotein receptor (ASGPR1) gene, a siRNA conjugate, a pharmaceutical composition comprising same, and use thereof. Each nucleotide in the siRNA is independently a modifie...  
WO/2024/047248A1
Cerebral small vessel disease (SVD) is a leading cause of stroke and a major contributor to cognitive decline and dementia in the population. Evidences indicate that blood brain barrier dysfunction may play a significant role in VD patho...  
WO/2024/047574A1
A pharmaceutical composition comprising: (a) one or more of a first pellet comprising i. a first core, and ii. a first coating on the first core, wherein the first coating comprises a mineralocorticoid receptor (MR) modulator and a first...  
WO/2024/046277A1
Disclosed in the present invention are a series of nitrogen-containing bridged heterocyclic compounds and a preparation method therefor, and particularly a compound represented by formula (I) and a pharmaceutically acceptable salt thereo...  
WO/2024/047227A1
The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical c...  
WO/2024/041460A1
The present invention provides compounds of Formula (I) : wherein all of the variables are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for the...  
WO/2024/042466A1
Polypeptides that traverse the blood-brain-barrier (BBB) are disclosed. The peptide can serve as BBB-traversing transport vehicles for delivering active agents from the circulation into across the BBB to contact cells and tissues within ...  
WO/2024/041236A1
A fusion protein ANGPTL3 monoclonal antibody-B comprising an ANGPTL3 monoclonal antibody is formed by fusing the ANGPTL3 monoclonal antibody with a sequence B. The fusion protein ANGPTL3 monoclonal antibody-B is used for treating disease...  
WO/2024/042220A1
The present invention relates to isolated polypeptides derived from stanniocalcin-2 (STC2), and polypeptide fragments and variants thereof useful for inhibiting proteolytic activity of the pregnancy-associated plasma protein-A (PAPP-A), ...  
WO/2024/043114A1
Disclosed is a composition that promotes expression of integrin α5. The composition comprises shell ginger leaf extract.  
WO/2024/042316A1
This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin doma...  
WO/2024/043242A1
Provided is a drug for preventing or treating heart failure, that is effective and that does not have a blood pressure lowering effect. The present invention pertains to: a pharmaceutical composition for preventing or treating heart fa...  
WO/2024/044571A1
This invention provides a method of treating hypertension in a hypertensive subj ect having a body mass index of at least 30, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twice per day...  
WO/2024/041746A1
The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of such compos...  
WO/2024/041596A1
Disclosed in the present application is use of phenytoin sodium as a mitophagy inducer. Provided in the present application is new use of the phenytoin sodium as the mitophagy inducer, which can selectively induce damaged mitochondria to...  
WO/2024/041330A1
Disclosed is use of LY2922470 in preparing a medicament for preventing or treating cerebrovascular diseases or tissue ischemia-reperfusion injury. The treatment effect of LY2922470 and TAK875 on ischemic stroke is evaluated by using an M...  
WO/2024/042494A1
The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or pr...  
WO/2024/040337A1
Cannabidiol, or a pharmaceutically acceptable prodrug, derivative, salt, or solvate thereof, for use in treating or preventing recurrent pericarditis is disclosed. The effectiveness of cannabidiol in attenuating the levels of interleukin...  
WO/2024/044228A1
Provided herein are compositions and methods for identifying COVID-19 subjects at risk for cerebrovascular events.  
WO/2024/043787A1
The present invention relates to an enriched LCMUFA composition comprising cetoleic acid. Furthermore, the invention relates to a method for providing an enriched composition comprising cetoleic acid, and to the use of such compositions.  
WO/2024/041372A1
Provided are a branched polypeptide vector and a variant thereof. The branched polypeptide has a sequence set forth in the following: Xaa1(P2)-Xaa1-Xaa1(P1)-Xaa1-Xaa1(P2), or Xaa1(P1)-Xaa1-Xaa1(P2)-Xaa1-Xaa1(P2)-Xaa1-Xaa1(P1), or Xaa1(P2...  
WO/2024/044594A2
This invention provides a method of treating hypertension in a hypertensive subject, the method administering to the subject, an amount of a diuretic and an amount of a CYP 11 β2 beta hydroxylase inhibitor once or twice per day, wherein...  
WO/2024/042061A1
The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe a...  
WO/2024/040334A1
A composition for maintaining vascular health, comprising a combination of Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract, and methods for preventing or treating cardiovascular diseas...  
WO/2024/038888A1
The present invention addresses the problem of providing technology for heightening a small intestinal absorption property of a peptide having physiological functionality. This problem is solved via a composition containing a peptide com...  
WO/2024/038284A1
Disclosed is a cohort of anti-proliferative microRNAs (miRs) wherein each member of the cohort (or combinations thereof) represent a target for modulating cell proliferation (and migration), influencing (or modulating) vascular remodelli...  
WO/2024/038132A1
The present invention relates to compounds of Formulas I to IV, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or preventi...  
WO/2024/039268A1
The present invention relates to the field of medicine, and more particularly to a method for treating a disease or disorder mediated by T-lymphocytes bearing a TRBV9 segment within the T-cell receptor, which includes administering an an...  
WO/2024/038398A1
The present invention provides a novel 5-fluoro-1-[(2-fluorophenyl) methyl]-1H-pyrazolo [3, 4-b] pyridine-3-carboximidamide formate compound of formula (IV) and process for preparation thereof. The present invention further provides for ...  
WO/2024/039822A1
Disclosed are novel thiol isomerase inhibitors and their use in the prevention or treatment of the development or progression of a disease or condition involving one or more of the extracellular thiol isomerases. Further disclosed a meth...  
WO/2024/036385A1
This disclosure pertains to the use of an anti-IL-6 antibody for the treatment of myocarditis and for managing the symptoms of myocarditis, in particular for (sub)acute myocarditis. This disclosure also pertains to the use of an anti-int...  
WO/2024/040119A2
Compositions and methods for safe and effective treatment for cardiac arrhythmias via increasing [K+]o and administering a sodium channel blocker are disclosed. In certain embodiments, the method includes administering a composition comp...  
WO/2024/036183A1
Heteroaryl-substituted thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones are 5-HT2B receptor antagonists and the compounds and their pharmaceutical compositions are useful in the treatment of disorders such as pulmonary arterial hypertension, ao...  
WO/2024/031445A1
Provided are processes for preparing heterocyclic compounds and compositions for use as MCT4 inhibitors.  
WO/2024/032713A1
Provided are compositions comprising the HKUOT-S2 protein, at least one peptide according to at least one of SEQ ID NO: 81-97, or proteins comprising an amino acid sequence according to at least one of SEQ ID NO: 81-97. Provided are meth...  
WO/2024/033460A1
The present invention relates to the use of co-processed excipients in continuous manufacturing of solid dosage forms.  
WO/2024/034652A1
The present disclosure provides: a tertiary amide derivative substituted by quaternary carbon that is useful as a medicine and a pharmaceutically acceptable salt of the tertiary amide derivative; a pharmaceutical composition comprising t...  
WO/2024/035884A1
Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: • a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically ...  
WO/2024/032589A1
Provided are a TGF-β inhibitor compound and use thereof. In particular, provided is a compound represented by formula (I) or formula (II) or an isotopically labeled compound, an optical isomer, a geometric isomer, a tautomer, an isomer ...  

Matches 51 - 100 out of 92,832